Zogenix Announces Conference Call and Webcast to Present Third Quarter 2011 Financial Results

Conference Call Scheduled for November 10, 2011 at 4:30 pm ET

 | Source: Zogenix Zogenix

SAN DIEGO, Nov. 4, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the third quarter ended September 30, 2011, after the market closes on Thursday, November 10, 2011, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 831-6243 (U.S.) or (617) 213-8855 (International); participant passcode: 83372419.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President and Chief Operating Officer Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning November 10, 2011 at 8:30 p.m. ET (5:30 p.m. PT) until November 17, 2011, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 92616527. A replay of the webcast will also be accessible on the Investor Relations website for one month, through December 10, 2011.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead product candidate, Zohydro™ (hydrocodone bitartrate), is a novel, oral, single-entity (without acetaminophen) extended-release capsule formulation currently in Phase 3 clinical trials for the management of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix's second DosePro product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia.

For additional information, please visit www.zogenix.com.

SUMAVEL®, DosePro®, ReldayTM and ZohydroTM are trademarks of Zogenix, Inc.



            








        

            

                

                    
Tags

                            
                                PHARMACEUTICALS
                            
                            
                                EARNINGS
                            
                            
                                CONFERENCE CALL
                            
                            
                                WEBCAST
                            

                



        




    

        

        
Contact Data

        


    
    

 
    



        

        
            GlobeNewswire